Andash® (Dapagliflozin and Metformin Extended-Release Tablets) Included in China's National Reimbursement Drug List to Enhance Access for Adults with Type 2 Diabetes

Achieving Blood Sugar Control and Cardiorenal Protection for a Wide Range of Diabetic Patients While Reducing Economic Burden

ShanghaiDecember 13, 2023 PR Newswire -- The National Healthcare Security Administration and the Ministry of Human Resources and Social Security announced the latest version of the "National Basic Medical Insurance, Work-related Injury Insurance, and Maternity Insurance Drug Catalog (2023Year)》(hereinafter referred to as the "Medical Insurance Catalog"), and will be implemented on2024Year1Month1Officially implemented on the date. AstraZeneca Andas释^®(General Name: Dapagliflozin Metformin Sustained-Release Tablets) has been included in the Class B "Medical Insurance Catalog" as the only one of its kind currently in China.*A once-daily, fixed-dose sodium-Glucose Cotransporter-2（SGLT2) Inhibitor and Metformin Hydrochloride Extended-Release Compound Preparation, after it was included in the medical insurance catalogWill benefit more2Type 2 diabetes patients, helping to reduce the economic burden, dual mechanisms work together to achieve blood sugar control and cardio-renal protection.

The base number of diabetes patients in China is huge, approximately1.29Hundred Million²，Among which2Type diabetes accounts for the entire diabetic population.90%Above³。As time goes by,2Continuous hyperglycemia in patients with type diabetes will lead to the further progression of their condition.¹，The biggest problem faced by patients is cardiorenal complications, whichAlso2The Main Cause of Disability and Mortality in Type Diabetes Patients⁴。

Professor Guo Lixin from Beijing Hospital stated: "On average, every three peopleOne in every two patients with type 2 diabetes has chronic kidney disease.⁵, diabetes has now become the main cause of chronic kidney disease and end-stage renal disease.⁶。At the same time, the risk of cardiovascular and cerebrovascular diseases increases in patients with diabetes.2 to 4 times, approximately 80% of patients eventually die from cardiovascular events.¹The coexistence of multiple diseases multiplies the mortality risk for patients with diabetes., causing serious disease and economic burden on society¹。”

As a chronicMetabolismDisease,Control of type 2 diabetes requires patients to undergo long-term medication treatment and maintain good adherence.⁷However, the current status of medication adherence among diabetes patients is not ideal. Currently, only 47% of diabetes patients in China are able to take their medication daily as directed by their doctors.⁸。More than half of2Patients with type diabetes need to take medication every day.3-6Tablet⁹Studies have shown that patients using a single oral hypoglycemic agent have higher medication adherence over a continuous one-year period compared to those using two agents simultaneously.45%¹⁰。

Professor Guo Lixin pointed out: "Poor medication adherencePoor control of diabetes, thereby increasing the risk of developingDiabetesThe risk of complications poses a threat to the patient's health.⁷. MoreoverVarious factors interact with each other.The patient and his family inThe economic burden of treating diabetes and its complications will significantly increase.。ThereforeChinese Diabetes PatientsUrgently needs something that can help itImprove MedicationComplianceInnovationMedicines, while also reducing the economic burden of medicines.”

2023Year6In the month, the sustained-release tablets of dapagliflozin and metformin hydrochloride received approval from the China National Medical Products Administration for use in conjunction with diet control and exercise, applicable to patients suitable for treatment with both dapagliflozin and metformin hydrochloride.2Adult patients with type diabetes improve blood glucose control. This combination formulation is for improving2Type diabetes patients' blood glucose control provides a first-line treatment option. It combines two antihyperglycemic drugs with complementary mechanisms of action: dapagliflozin (trade name: Forxiga), a sodium-Glucose Cotransporter-2（SGLT2) inhibitor, which was previously approved in China for the treatment of adults2Type 2 diabetes, symptomatic chronic heart failure, and chronic kidney disease, as well as metformin hydrochloride extended-release tablets, a once-daily oral biguanide tablet.

Mr. Lai Minglong, General Manager of AstraZeneca China, said: "AstraZeneca is always committed to continuously improving the wide accessibility of innovative drugs in China.。The inclusion of dapagliflozin metformin sustained-release tablets in the Class B National Medical Insurance Catalog will allow more...2TypePatients with diabetes have access to treatment options that can achieve blood glucose control and provide cardiorenal protection. In the future, we will continue to take patients' needs as our responsibility, leveraging AstraZeneca's deep expertise in cardiovascular, renal, and metabolic fields from global to China, to further develop more innovative therapies for diabetes, expand drug accessibility, and benefit more patients in China." 

About2Type 2 Diabetes

2Type 2 diabetes is a chronic disease characterized by pathophysiological defects that lead to elevated glucose levels.Or Hyperglycemia¹⁰. Over time, persistent hyperglycemia will lead to the further progression of the disease.¹⁰. It is expected that by2045By the year, the number of people with diabetes will reach7.83Hundred Million¹⁰. In China,2Type diabetes accounts for the entire diabetic population.90%Above²Many patients have poor blood glucose control, low medication adherence, and there remains a significant unmet medical need.^10,11。

About Dapagliflozin Metformin Sustained-Release Tablets

Dapagliflozin Metformin Sustained-Release Tablets are the first Dapagliflozin (SGLT2A compound preparation of inhibitor and metformin extended-release (biguanide class), taken once daily.In conjunction with diet control and exercise, suitable for patients appropriate for Dapagliflozin and Metformin Hydrochloride treatment.Improved Glycemic Control in Adult Patients with Type 2 Diabetes。

About Dapagliflozin

Dapagliflozin is the first in its class sodium-Glucose Cotransporter-2（SGLT2) inhibitor, taken orally once daily. As scientific research continues to uncover potential connections between the heart, kidneys, and pancreas, studies have also shown dapagliflozin's efficacy in slowing cardiorenal disease progression and providing organ protection.^13-15. Damage to a single organ can lead to dysfunction in other organs, which is also the case worldwide, including2Type diabetes, heart failure, and chronic kidney disease (CKD) among the leading causes of death^15-17 。

*As of2023Year12Month

Disclaimer: This material is not intended for any promotional purposes, and the relevant information should not be used as advice for treatment or use. For any related questions, please consult a healthcare professional.

References: